Needham analyst Michael Matson (NYSE:MATX) maintained a Buy rating on Medtronic (NYSE:MDT) on Tuesday, setting a price target of $145, which is approximately 24.05% above the present share price of $116.89.
Matson expects Medtronic to post earnings per share (EPS) of $0.57 for the fourth quarter of 2021.
The current consensus among 16 TipRanks analysts is for a Strong Buy rating of shares in Medtronic, with an average price target of $149.
The analysts price targets range from a high of $165 to a low of $138.
In its latest earnings report, released on 07/31/2021, the company reported a quarterly revenue of $7.99 billion and a net profit of $896 million. The company's market cap is $157.31 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.6% and a 59.36% success rate.
Founded in 1949, Medtronic Plc, a medical technology company, develops, manufactures, distributes, and sells device-based medical therapies and services worldwide. It operates through four segments, including Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The company is headquartered in Dublin, Ireland.